Please login to the form below

Not currently logged in
Email:
Password:

malignant glioma

This page shows the latest malignant glioma news and features for those working in and with pharma, biotech and healthcare.

BMS signs $1.74bn deal to boost immuno-oncology portfolio

BMS signs $1.74bn deal to boost immuno-oncology portfolio

malignant cells. . ... and malignant glioma.

Latest news

  • BMS' Opdivo set for early access in UK BMS' Opdivo set for early access in UK

    Until now, the only PIM granted under the scheme was for Northwest Biotherapeutics' cell-based therapy DCVax-L for a form of brain cancer known as malignant glioma.

  • FDA grants orphan status to Activartis’ brain cancer immunotherapy FDA grants orphan status to Activartis’ brain cancer immunotherapy

    Regulator says AV0113 has potential in rare cancer malignant glioma. Activartis received a boost this week when the US Food and Drug Administration (FDA) granted orphan drug status to its investigational ... The Austria-based biotech said the US

  • Roche's Avastin gains Japanese approval for brain cancer Roche's Avastin gains Japanese approval for brain cancer

    The Japanese drug regulator has approved Roche's Avastin (bevacizumab) for malignant glioma and newly diagnosed glioblastoma (GBM), in combination with radiotherapy and temozolomide chemotherapy. ... The estimated number of newly diagnosed malignant

  • Ark files documentation on Cerepro

    gene-based therapy for the treatment of operable malignant glioma (brain cancer). ... Malignant glioma is a fatal form of brain tumour that is usually confined to the brain.

  • Close but no cigar

    Both are being reviewed by the EMEA for the treatment of head and neck cancer and glioma, respectively. ... glioma, compared with patients receiving standard care alone (either surgery and radiotherapy or surgery and radiotherapy plus temozolomide).

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics